OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.260
+0.020 (1.61%)
At close: May 12, 2025, 4:00 PM
1.250
-0.010 (-0.79%)
After-hours: May 12, 2025, 7:49 PM EDT
OPKO Health Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for OPKO Health stock have an average target of 2.75, with a low estimate of 2.25 and a high estimate of 3.00. The average target predicts an increase of 118.25% from the current stock price of 1.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for OPKO Health stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Barrington Research | Barrington Research | Buy Maintains $2.25 | Buy | Maintains | $2.25 | +78.57% | May 1, 2025 |
JP Morgan | JP Morgan | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Apr 25, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +138.10% | Apr 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +138.10% | Mar 19, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +138.10% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
669.14M
from 713.14M
Decreased by -6.17%
Revenue Next Year
723.43M
from 669.14M
Increased by 8.11%
EPS This Year
-0.30
from -0.08
EPS Next Year
-0.22
from -0.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 719.0M | 818.0M | 901.3M | ||
Avg | 669.1M | 723.4M | 830.7M | ||
Low | 623.8M | 616.4M | 770.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 0.8% | 22.2% | 24.6% | ||
Avg | -6.2% | 8.1% | 14.8% | ||
Low | -12.5% | -7.9% | 6.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.19 | -0.13 | -0.11 |
Avg | -0.30 | -0.22 | -0.11 |
Low | -0.59 | -0.43 | -0.12 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.